PeSuLife: Evaluation of Functional Outcomes After Laparoscopic Promontofixation (PFL).

Sponsor
University Hospital, Caen (Other)
Overall Status
Recruiting
CT.gov ID
NCT03919123
Collaborator
(none)
200
1
45
4.4

Study Details

Study Description

Brief Summary

Prolapse of the pelvic organs is a common pathology in women with a strong impact on the quality of life. Its prevalence tends to increase due to increased life expectancy and obesity.

The main treatment is surgical and involves all organ specialists dealing with pelvic-perineal functional disorders: urologists, gynecologists, digestive surgeons.

Our team wishes to evaluate, on a cohort of patients operated at the Caen University Hospital, the functional uro-gynecologic, digestive and sexual results of pelvic organ prolapse (POP) repair by Laparoscopic Promontofixation (PFL) through symptoms and quality of life validated questionnaires (QoL).

The analysis of the responses to these questionnaires will allow us to evaluate the functional results in the short and medium term (from 6 months to 5 years)

Condition or Disease Intervention/Treatment Phase
  • Other: Evaluation of laparoscopic promontofixation

Detailed Description

This is a retrospective cohort study conducted at the Universitary hospital of Caen in three surgical departments (gynecology, urology and digestive surgery).

Patients who had a laparoscopic promontofixation will be asked to respond to validated questionnaires of symptoms and quality of life after their surgery (PFDI-20, ICIQ-SF, PFIQ-7) and satisfaction (PGI-I)

Study Design

Study Type:
Observational
Anticipated Enrollment :
200 participants
Observational Model:
Cohort
Time Perspective:
Retrospective
Official Title:
Evaluation of Functional Outcomes and Quality of Life After Laparoscopic Promontofixation (PFL). Unicentric Retrospective Cohort Study (PeSuLife)
Actual Study Start Date :
Jan 1, 2019
Anticipated Primary Completion Date :
Jun 1, 2022
Anticipated Study Completion Date :
Oct 1, 2022

Outcome Measures

Primary Outcome Measures

  1. Effect of laparoscopic promontofixation on urogynecologic and digestive symptoms [3 years]

    The main objective is to collect the PFDI-20 score after the surgery. This score was developped to evaluate the genital, anorectal and digestive symptoms related to prolapse

Secondary Outcome Measures

  1. Effect of laparoscopic promontofixation on urinary incontinence [3 years]

    Assessment of the ICIQ-SF score, a specific score developped to assess the impact urinary incontinence

  2. Sexual impact of laparoscopic promontofixation [3 years]

    Evaluation of the PISQ-12 score after laparoscopic promontofixation. This score was developped specifically to evaluate sexual troubles in case of genital prolapse

  3. Evaluation of quality of life after prolapse surgery [3 years]

    Evaluation of the quality of life using a score specifically developped in case of genital prolapse : the PFIQ-7 score

  4. Assessment of patient satisfaction after surgery [3 years]

    Evaluation of the quality of life using the PGI-I score, developped to quantify the effect of urinary or prolapse treatments

  5. Specific evaluation of functional outcomes of laparoscopic rectopexy in rectocele or elytrocele indications [3 years]

    Evaluation of the PFDI-20 score in women undergoing laparoscopic rectopexy

  6. Comparison of the different scores according to the operative indication (anterior promontofixation, double promontofixation, rectopexy alone) [3 years]

    Comparison of the PFDI-20 scores according to the operative indication

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No
Inclusion Criteria:

Patients who have had a laparoscopic promotofixation for genital prolapse at the University Hospital of Caen between 2013 and 2018 in the departments of gynecology, urology and digestive surgery.

Patient who received written information and agreed to participate in the study

Exclusion Criteria:

Minor patient, under guardianship, under trusteeship Patient not understanding French Refusal to participate in the study

Contacts and Locations

Locations

Site City State Country Postal Code
1 University Hospital Caen Normandie France 14 000

Sponsors and Collaborators

  • University Hospital, Caen

Investigators

  • Study Director: Anne-Cécile Pizzoferrato, MD, PhD, Universitary hospital of Caen

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
University Hospital, Caen
ClinicalTrials.gov Identifier:
NCT03919123
Other Study ID Numbers:
  • 2018-A02927-48
First Posted:
Apr 18, 2019
Last Update Posted:
Apr 18, 2019
Last Verified:
Apr 1, 2019
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by University Hospital, Caen
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 18, 2019